Bristol-Myers Squibb (BMY) Tops Q4 EPS by 5c, Offers FY Guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.46, $0.05 better than the analyst estimate of $1.41. Revenue for the quarter came in at $11.07 billion versus the consensus estimate of $10.73 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2021 EPS of $7.35-$7.55, versus the consensus of $7.45.

• Bristol Myers Squibb is providing 2021 GAAP EPS guidance in the range of $3.12-$3.32 and is increasing its non-GAAP EPS guidance range from $7.15 - $7.45 to $7.35 - $7.55. Both GAAP and non-GAAP guidance assume current exchange rates. Key 2021 GAAP and non-GAAP line item guidance assumptions are:
• Worldwide revenues increasing in the high-single digits.
• Gross margin as a percentage of revenue to be approximately 80.5%.
• Marketing, selling and administrative expenses to be in-line with 2020 levels for GAAP and increasing in the low-single digit range for non-GAAP.
• Research and development expenses decreasing in the high-single digits for GAAP and increasing in the mid-single digits for non-GAAP.
• An effective tax rate of approximately 22% for GAAP and approximately 16% for non-GAAP.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• FDA accepts Bristol Myers Squibb's mezigdomide application for myeloma
• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Benchmark Reiterates Buy Rating on Cal-Maine Foods (CALM) as Q4 Estimates Trimmed